BioSpace News Archive

The U.S. Food and Drug Administration continues to play a critical role in the multifaceted all-of-government response to the COVID-19 pandemic, which includes, among other things, facilitating medical countermeasures to treat and prevent the disease, and surveilling the medical product and food supply chains for potential shortages or disruptions and helping to mitigate such impacts, as necessary.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-term outcomes studies of sotagliflozin, SCORED and SOLOIST, designed to demonstrate benefits in and support labeling for heart failure and chronic kidney disease.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial results after the market close on Thursday, March 26, 2020.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three months and full year ended December 31, 2019.

Thirty semi-finalists have been named in the annual “Make Your Medical Device Pitch for Kids!” competition presented by the National Capital Consortium for Pediatric Medical Devices (NCC-PDI)

BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at the upcoming American College of Cardiology’s 69 th Annual Scientific Session together with the World Congress of Cardiology ( ACC.20/WCC Virtual *). Data from the Phase 2 dose-ranging clinical trial will inform patient identification, dosing and potential endpoints for futu

Bio-Rad Laboratories, Inc. announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 compared to existing test methods that are performed using qPCR.

Javara Inc., the industry leading Integrated Research Organization (“IRO”), who partners with healthcare organizations to procure and conduct clinical trials, announces a dedicated offering to support the clinical development efforts for a COVID-19 vaccine and treatment options along with a spectrum of infectious diseases

Since the outbreak of COVID-19, people around the globe have been eagerly awaiting a real breakthrough on its treatment.